Related Experiment Video
Updated: Jul 3, 2026
10:03
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Cytomegalovirus vaccine development.
1Division of Pediatric Infectious Diseases, Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, 2001 6th Street SE, Minneapolis, MN 55455, USA. schleiss@umn.edu
Current Topics in Microbiology and Immunology
|July 22, 2008
Summary
Developing a human cytomegalovirus (HCMV) vaccine remains challenging due to unclear immune correlates and target populations. Further research and public education are crucial for preventing HCMV disease.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Human cytomegalovirus (HCMV) infection is widespread but can cause severe disease in high-risk groups like transplant recipients, HIV-infected individuals, and fetuses.
- Despite over 30 years of vaccine development efforts, no licensed HCMV vaccine is available.
- Immunity to HCMV can reduce disease severity, highlighting the need for effective vaccines.
Purpose of the Study:
- To review strategies explored for HCMV vaccine development.
- To summarize current clinical trials and novel technologies for HCMV vaccine research.
- To address the challenges hindering the licensure of an HCMV vaccine.
Main Methods:
- Review of historical and ongoing HCMV vaccine development strategies.
- Analysis of challenges in clinical trials and target population identification.
- Exploration of novel technologies for future vaccine considerations.
Main Results:
- Key challenges include unclear immune correlates of protection and uncertainty regarding essential viral vaccine components.
- Clinical trials have often focused on populations not relevant to preventing congenital HCMV infection.
- Insufficient public and targeted education about HCMV infection persists.
Conclusions:
- Successful HCMV vaccine development requires clarifying protective immunity and identifying optimal vaccine targets.
- Future efforts must consider diverse populations, including pregnant women and the general public.
- Novel technologies and enhanced public awareness are essential to overcome hurdles in HCMV prevention.
Related Concept Videos
01:27Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:17Poliomyelitis
Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...